Kondo M, Nonomura N, Miki T, Kojima Y, Yokoyama M, Nakano E, Okuyama A
Department of Urology, Osaka University Medical School, Osaka, Japan.
Oncology. 1998 Nov-Dec;55(6):588-93. doi: 10.1159/000011917.
Adjuvant immunotherapy with interferons and/or interleukin 2 (IL-2) is widely used for advanced kidney cancer. However, the results are not satisfactory so far. The purpose of this study is to evaluate the inducible activity of lymphokine-activated killer (LAK) cells against autologous human renal cell carcinoma. The effect of interleukin 7 (IL-7) on IL-2-induced LAK activity was assessed by the autologous assay system which we have established. Peripheral blood lymphocytes from patients with renal cell carcinoma were stimulated with IL-2 and/or IL-7, and tested for antitumor activity against autologous renal cell carcinoma. In all 10 cases tested, IL-7 alone induced LAK activity. Moreover, IL-2-induced LAK activity was augmented by the concomitant addition of IL-7. Flow cytometry revealed an increase in IL-2-receptor-positive lymphocytes following incubation with IL-7. These results suggest that combination therapy using IL-2 and IL-7 may be a useful treatment for patients with advanced renal cell carcinoma.
干扰素和/或白细胞介素2（IL-2）辅助免疫疗法广泛应用于晚期肾癌。然而，目前结果并不令人满意。本研究旨在评估淋巴因子激活的杀伤细胞（LAK）对自体人肾细胞癌的诱导活性。通过我们建立的自体检测系统评估白细胞介素7（IL-7）对IL-2诱导的LAK活性的影响。用IL-2和/或IL-7刺激肾细胞癌患者的外周血淋巴细胞，并检测其对自体肾细胞癌的抗肿瘤活性。在所有检测的10例病例中，单独使用IL-7可诱导LAK活性。此外，同时添加IL-7可增强IL-2诱导的LAK活性。流式细胞术显示，与IL-7孵育后，IL-2受体阳性淋巴细胞增加。这些结果表明，使用IL-2和IL-7的联合疗法可能是晚期肾细胞癌患者的一种有效治疗方法。
